Trials / Completed
CompletedNCT01316458
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.
Conditions
- Prostatic Neoplasm
- Genital Neoplasms, Male
- Neoplasms, Abdominal
- Urogenital Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Antineoplastic Agents
- Imatinib
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STI571 (Glivec®) |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2010-07-01
- First posted
- 2011-03-16
- Last updated
- 2017-06-01
Locations
13 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01316458. Inclusion in this directory is not an endorsement.